WO/GA/34/16
ITEM 17 OF THE CONSOLIDATED AGENDA:
REPORT ON THE SPECIAL SESSIONS OF THE STANDING COMMITTEE ON COPYRIGHT AND RELATED RIGHTS REGARDING THE PROPOSED DIPLOMATIC CONFERENCE ON THE PROTECTION OF THE RIGHTS OF BROADCASTING ORGANIZATIONS
202 Discussions were based on document WO/GA/34/8.
203 Referring to document WO/GA/34/8, the Secretariat summarized the previous discussions and the recommendation from the Second Special Session of the Standing Committee on Copyright and Related Rights (SCCR).
Continue Reading →
From AstraZeneca’s 20-F, section on Risk Factors, for fiscal year ended December 31, 2012. Number of words in Item 1A: 8621 Compulsory licensing of patents: 45 3D. Risk Factors The information (including tabular data) set forth or referenced under the… Continue Reading →
From Amgen’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.
Item 1A. RISK FACTORS
Continue Reading →
From Eli Lilly’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 1A: 2168
Compulsory licensing of patents: 0
Item 1A. Risk Factors
Continue Reading →
From Gilead’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in section 1A: 12709
Words on compulsory licenses: 396
ITEM 1A. RISK FACTORS
Continue Reading →
From Johnson & Johnson’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 1A: 1314
Compulsory licensing of patents: 0
Item 1A.RISK FACTORS
Continue Reading →
From Roche’s Risk Management and Compliance site, section on Risk Factors, dated May 2012.
Number of words in Risk Factor document: 360
Compulsory licensing of patents: 0
Risk factors
Principal risks and uncertainties
Continue Reading →
From Sanofi’s 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 3D: 10577
Compulsory licensing of patents: 43
3D. Risk Factors
Continue Reading →
From Novartis’ 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 3D: 10297
Compulsory licensing of patents: 55
Earthquake risk: 96
3.D Risk Factors
Continue Reading →
From GlaxoSmithKline’s 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012. Number of words in Item 3D: 6304 Compulsory licensing of patents: 42 3.D Risk factors Principal risk factors and uncertainties There are risks and uncertainties… Continue Reading →